In This Episode
“I walked out of that conference feeling like there are a lot of really smart people trying to find the solution to this disease. So that was the optimistic part.”
The Alzheimer’s Podcast is back for 2020! We’re back with part 2 of the conversation between me and Phil Gutis about his trip to the Clinical Trials on Alzheimer’s Disease conference, or CTAD, in December 2019. The conference was a super big deal because Biogen presented on why they now believe aducanumab is a drug worth pursuing after all. For more on the roller coaster of this story, check out the show notes, where we link to the real-life drama.
Meanwhile, back to Phil. We affectionately call him our Assistant Sherpa here on the show but he’s actually kind of a big deal. Phil covered the conference for Being Patient, and was likely the only person present who’d been part of the aducanumab clinical trials.
In this episode, we may sound cynical but I think we’d both prefer to call it truthful. We discuss the financial implications of a successful drug treatment and recap the changes Phil made in 2019 and the impact they’ve had on his ability to navigate life.
We pick up just after Phil said he believes a realistic timeline for FDA approval is likely to be 5 years.
- Biogen Trial Participant Seeks to Understand Science Behind Alzheimer’s Drug
For Care Partners
Dementia can last 20+ years.
That's a long time to struggle with trial and error!
If you're ready to step out of overwhelm (and anxiety about the future), click the button below now to schedule your complimentary Dementia Caregiver Strategy call with Christy. (Mobile users, click HERE.)
It's time for you and your person to step into the life you deserve.
Mike Good founded The Alzheimer’s Podcast in May 2017. Christy appears as a guest in episodes 15, 19, 21, and 23-26. She became the featured expert on the show starting with episode 28 and appears in every episode after, except 56. When Mike decided to follow his bliss, Christy took over the show in January 2019.
If you have questions or comments for Phil (or me), please let us know! We love hearing from you 🙂